857 related articles for article (PubMed ID: 28600319)
1. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiome and nonalcoholic fatty liver diseases.
Zhu L; Baker RD; Baker SS
Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
[TBL] [Abstract][Full Text] [Related]
3. Intestinal microbiota and nonalcoholic steatohepatitis.
Brandl K; Schnabl B
Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
[TBL] [Abstract][Full Text] [Related]
4. The role of the gut microbiota in NAFLD.
Leung C; Rivera L; Furness JB; Angus PW
Nat Rev Gastroenterol Hepatol; 2016 Jul; 13(7):412-25. PubMed ID: 27273168
[TBL] [Abstract][Full Text] [Related]
5. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
6. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
Cho MS; Kim SY; Suk KT; Kim BY
J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
[TBL] [Abstract][Full Text] [Related]
7. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
Jayakumar S; Loomba R
Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Buffet C
Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
[TBL] [Abstract][Full Text] [Related]
9. The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome.
Quigley EM; Abu-Shanab A; Murphy EF; Stanton C; Monsour HP
Semin Liver Dis; 2016 Sep; 36(4):312-316. PubMed ID: 27997970
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
12. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
Wieland A; Frank DN; Harnke B; Bambha K
Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
[TBL] [Abstract][Full Text] [Related]
13. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
[TBL] [Abstract][Full Text] [Related]
14. NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice.
Cavallari JF; Pokrajac NT; Zlitni S; Foley KP; Henriksbo BD; Schertzer JD
Am J Physiol Endocrinol Metab; 2020 Aug; 319(2):E305-E314. PubMed ID: 32516028
[TBL] [Abstract][Full Text] [Related]
15. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
16. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.
Sharpton SR; Ajmera V; Loomba R
Clin Gastroenterol Hepatol; 2019 Jan; 17(2):296-306. PubMed ID: 30196156
[TBL] [Abstract][Full Text] [Related]
17. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
18. Diet and gut microbiome in fatty liver and its associated liver cancer.
Pan Y; Zhang X
J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
[TBL] [Abstract][Full Text] [Related]
20. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
